Published in Ann Neurol on March 01, 2004
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology (2014) 3.15
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev (2009) 1.31
Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One (2011) 1.25
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep (2013) 1.21
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses (2013) 1.15
Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol (2011) 1.13
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology (2011) 1.05
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord (2015) 1.03
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther (2005) 1.02
Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis (2013) 1.00
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (2014) 0.98
Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect (2011) 0.96
The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS (2009) 0.94
Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology (2012) 0.93
Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya. PLoS One (2012) 0.93
HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep (2013) 0.91
Human polyomavirus reactivation: disease pathogenesis and treatment approaches. Clin Dev Immunol (2013) 0.89
Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol (2015) 0.88
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener (2014) 0.87
Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.87
Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med (2009) 0.84
Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis (2007) 0.81
BK virus associated meningoencephalitis in an AIDS patient treated with HAART. AIDS Res Ther (2007) 0.81
Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia. PLoS One (2012) 0.80
Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation (2010) 0.80
Progressive multifocal leucoencephalopathy in HIV/AIDS: observational study from a tertiary care centre in northern India. Indian J Med Res (2013) 0.80
Three-decade neurological and neurocognitive follow-up of HIV-1-infected patients on best-available antiretroviral therapy in Finland. BMJ Open (2015) 0.80
LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY. Rev Inst Med Trop Sao Paulo (2015) 0.79
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. AIDS Res Ther (2015) 0.79
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother (2008) 0.79
Update on opportunistic infections in the era of effective antiretroviral therapy. Infect Dis Clin North Am (2014) 0.79
Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsychol (2010) 0.79
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin Dev Immunol (2013) 0.78
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrob Agents Chemother (2012) 0.78
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol (2013) 0.78
Brain magnetic resonance imaging screening is not useful for HIV-1-infected patients without neurological symptoms. AIDS Res Hum Retroviruses (2014) 0.77
¹⁸F-FDG PET/CT in HIV-related central nervous system pathology. Eur J Nucl Med Mol Imaging (2013) 0.77
PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. Eur J Nucl Med Mol Imaging (2017) 0.75
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat (2012) 0.75
The Role of HIV Infection in Neurologic Injury. Brain Sci (2017) 0.75
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. AIDS Res Treat (2016) 0.75
Impact of antiretroviral therapy on HIV-related brain injury. Clin Infect Dis (2011) 0.75
Cross-sectional study of unexplained white matter lesions in HIV positive individuals undergoing brain magnetic resonance imaging. AIDS Patient Care STDS (2014) 0.75
Combined antiretroviral therapy and the incidence of acquired immunodeficiency syndrome-related central nervous system diseases. Ann Neurol (2004) 0.75
Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. J Acquir Immune Defic Syndr (2017) 0.75
A paradoxical decline: intracranial lesions in two HIV-positive patients recovering from cryptococcal meningitis. BMJ Case Rep (2015) 0.75
Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection. Neurol Sci (2011) 0.75
Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study. Clin Epidemiol (2017) 0.75
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal. J Clin Microbiol (2003) 3.03
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav (2004) 2.53
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. AIDS (2005) 2.48
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials (2010) 2.10
Chronic renal failure among HIV-1-infected patients. AIDS (2007) 2.07
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis (2011) 1.96
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis (2013) 1.90
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther (2011) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother (2007) 1.89